The Institute for Clinical and Economic Review wants to assess the
cost-effectiveness of breakthrough drugs for cystic fibrosis.
But their analysis overlooks key points.
ICER Misses the Numbers That Matter
Menu
The Institute for Clinical and Economic Review wants to assess the
cost-effectiveness of breakthrough drugs for cystic fibrosis.
But their analysis overlooks key points.
© 2024, Alliance for Patient Access.